Table 2

Patient HLA types and ELISpot results, showing the sum of delta (background subtracted) IFN-γ spot forming cells (SFC) at weeks 0, 16 and 65 for each patient for whom ELISpot analysis was possible.
Patient
 HLA type (peptides used)
 Sum of Δ IFN-γ SFC/106 PBMC




Week 0
 Week 16
 Week 65
Group A
Gag
 Pol
 Nef
 Gag
 Pol
 Nef
 Gag
 Pol
 Nef
1
 A1 (g1)
A2 (g2, p1, p2, p3, n1)
B7 (g8, n2)
B18 (n8)
 20
 20
 260
 0
 0
 150
 20
 10
 680
16
 A2, (g2, p1, p2, p3, n1)
B44 (g17, p13, p14)
 50
 90
 110
 940
 850
 320
 740
 1200
 20
36
 A2, (g2, p1, p2, p3)
A23, (g13)
B27, (n9)
B49 (n8)
 F
 F
 F
 70
 60
 30
 230
 280
 370
52
 A11, (g4, g5, p5, n2)
A9, (none identified)
B35A, (g14, p10)
B61 (g23, p15, n13)
 670
 470
 295
 910
 405
 1280
 370
 215
 165
54
 A2, (g2, p2, n1)
A11, (g5, p5)
B27, (n9)
B35A (g14, p10)
 80
 190
 30
 F
 F
 F
 290
 240
 160
Group B
Gag
 Pol
 Nef
 Gag
 Pol
 Nef
 Gag
 Pol
 Nef
7
 A2, (g2, p2, p3, n1)
A24, (g6)
B55, (g18)
B57B (g19, g20, 21, g22)
 500
 30
 0
 1310
 120
 20
 1340
 190
 0
35
 A3, (g3)
A32, (p8)
B7 (g8, n5)
 50
 110
 75
 130
 70
 25
 185
 135
 115
57
 A1, (g1)
B8 (g9, g10, g11, g12, p9, n6, n7)
 490
 50
 130
 190
 30
 20
 450
 70
 120
Group C
Gag
 Pol
 Nef
 Gag
 Pol
 Nef
 Gag
 Pol
 Nef
4
 A1, (g1)
A26, (g7)
B27, (n9)
B57B(g19, g20, g21, g22, n12)
 220
 nd
 50
 130
 nd
 40
 520
 nd
 60
11
 A1, (g1)
A2, (g2, p1, p2, p3, n1) B35A, (g14, g15, g16, p10, p11, p12, n10, n11)
B57B(g19, g20, g21, g22, n12)
 3820
 3140
 2990
 90
 50
 20
 2820
 2760
 960
14
 A1, (g1)
A2, (g2, p1, p2, p3, n1)
B57B,(g19, g20, g21, g22, n12)
B62 (none identified)
 F
 F
 F
 1140
 130
 20
 100
 30
 70
34
 A3, (g3)
A29, (p7)
B35A, (g14, g15, p10, n10)
B44 (g17, p13, p14)
 320
 100
 0
 F
 F
 F
 520
 80
 10
Group D
Gag
 Pol
 Nef
 Gag
 Pol
 Nef
 Gag
 Pol
 Nef
13
 A2, (g2, p1, p2, n1)
A11, (g4, p4, n2)
B8, (g9, p9, n6)
B62 (none identified)
 50
 20
 70
 730
 1890
 1190
 390
 640
 240
22
 A1, (g1)
A2, (g2, p2, n1)
B7, (g8, n5)
B35A (g14, g15, p10, n11)
 270
 80
 120
 F
 F
 F
 60
 40
 260

F denotes assay failure. IFN-γ (interferon-gamma), PBMC (peripheral blood mononuclear cells), SFC (spot forming cells). AHLA B35 is associated with rapid progression in HIV-1 infection. BHLA B57 is associated with slow/non progression in HIV-1 infection.

Hardy et al. Journal of Immune Based Therapies and Vaccines 2007 5:6   doi:10.1186/1476-8518-5-6